All lobbying filings
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.)
DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) filed a Q3 report for DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) on October 13, 2026.
Lobbying for DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) · Biopharmaceutical organization developing medicines for disorders of the brain.
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 13, 2026
Expenses
$130,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Maryland
Government bodies contacted
2
Lobbying activity
1
Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.